CD274 and neoplasm: MICA also demonstrated superior performance over clinically approved tests such as PD-L1 expression (AUC = 0.66; 95% CI: 0.54–0.77; P < 0.05) and tumor mutation burden (TMB) (AUC = 0.59; 95% CI: 0.37–0.80; P < 0.05).